Solentim sets new standards in productivity with the launch of ICON and STUDIUS; accelerating assu – PharmiWeb.com

Bournemouth, UK, 25th January 2021 / SciadNewswire /Solentim, the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells, is delighted to launch two new solutions to enhance the development of therapeutic antibodies. ICON is a benchtop system for the rapid stratification of high productivity clones and STUDIUSis a proprietary software platform that delivers unparalleled data on each cells journey through cell line development.

The all-in-one ICON system assesses specific productivity using rapid on-board assays for the three critical quality attributes of titer, cell number and cell viability. Using plate-based imaging for static plate cell counting and cell suspension automated cell counting with viability for fed-batch, ICON generates normalized cell productivity data. This information enables cell line development scientists to separate the promising clones from the rest, saving resources and accelerating workflows.

STUDIUS is Solentims bespoke data management solution for cell line development. The over-arching platform is designed for Solentims instruments to provide control, management and reporting in the pursuit of lead candidates. STUDIUS delivers an unparalleled perspective on the journey of each individual cell, from seeding to selection, and intelligently manages verified information from multiple sources to enable scientists to select high value cells. Importantly, STUDIUS protects data, providing data auditing and integrity with a suite of tools applicable for laboratories working under 21 CFR Part 11 compliance. Using the novel HISTORYTREE visualization, STUDIUS maps each cells journey, presenting all the necessary cell data for regulatory approval in one report.

Dr Mark Truesdale, CEO, Solentim, said: Our cell line development ecosystem of instruments Cell Metric, VIPS and now ICON provides the optimal workflow solution for seeding, growing and selecting the highest value cells with quality evidence of assurance of clonality. Our protected ecosystem ensures data integrity, and our data-driven reporting prepares you for regulatory approval from day one.

To find out how ICON and STUDIUS can take your cell line development workflow to the next level, or to arrange a product demo, please contact us.

Corporate Contacts:Solentim LtdDuncan Borthwick, Global Marketing ManagerT: +44 (0)1202 798510E: duncan.borthwick@solentim.com

PR Contact:Sciad Communications LtdEmma Pickup/Richard AndersonT: +44 (0)20 3405 7892E:solentim@sciad.com

About SolentimSolentim is the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells. In the pursuit of new biological medicines, our data rich portfolio of industry accepted technologies drives accelerated development of Master Cell Banks. For our customers,whichincludemost of the worlds leading pharmaceutical and biotherapeutics companies,we arethe partner of choicefor facilitatingthehighestlevel of assurance in cell line developmentfor therapeutic protein and viral vector production.

Our portfolio of proven and innovative instruments (including VIPS, Cell Metric, Cell MetricCLD and ICON) are designed for single cell cloning and assurance of monoclonality.Combined with enabling reagents (includingInstiGRO and Leap-InTransposase) from our partners, and our unparalleled domain expertise,we transformthe speed and efficiency ofclonally-derivedMasterCellBank development. Our customers trust in our technologyto ensure they areconfidently prepared for regulatory review.

More here:

Solentim sets new standards in productivity with the launch of ICON and STUDIUS; accelerating assu - PharmiWeb.com